Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Not a peripheral story

    Beyond peripheral autoimmunity in Type I diabetes

    By looking in pancreatic islets rather than blood, a UMass team has uncovered a trove of new antigens that drive Type I diabetes.

    Published on 12/1/2016
  • Figure: A lethal halo

    Not a peripheral story Targets & Mechanisms A lethal halo In a Nature Medicine study published in October, researchers from the University of Massachusetts Medical School profiled islet-infiltrating T cells from …

    Published on 12/1/2016
  • Figure: Stages of withdrawal

    Going against the gut Targets & Mechanisms Stages of withdrawal An NIH and Emory University team designed a five-stage protocol to test whether a mAb against integrin α4β7 would allow monkeys infected with SIV, the…

    Published on 11/3/2016
  • Going against the gut

    Why blocking T cell entry into the gut could get HIV patients off of ART

    An NIH group wants to boost immunity in HIV and wean patients off ART by blocking entry of T cells to the gut, where most of the virus lurks.

    Published on 11/3/2016
  • Cancer's Phoenix

    A safer IL-2-based immunotherapy without compromised efficacy

    Courier Therapeutics may have solved the longstanding problem of how to avoid the lethal side effects of IL-2 cancer immunotherapy without compromising efficacy.

    Published on 10/27/2016
  • Figure: Aim intermediate

    Cancer's Phoenix Targets & Mechanisms Aim intermediate To avoid dose-limiting toxicities associated with recombinant IL-2, researchers at Washington University in St. Louis have created a fusion protein that …

    Published on 10/27/2016
  • Figure: Check This Out

    Cancer's Phoenix Targets & Mechanisms Check This Out Therapeutic response rates for metastatic renal cell carcinoma (RCC) patients treated with high-dose IL-2 or anti-PD1 antibody therapies, broken down by complete…

    Published on 10/27/2016
  • Table: BioCentury Product Profile

    Cancer's Phoenix Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A fusion protein comprising a mutant form of IL-2 with diminished CD25 binding, linked to the …

    Published on 10/27/2016
  • Table: Everything old is new again

    Cancer's Phoenix Targets & Mechanisms Everything old is new again IL-2-based therapeutics in clinical and preclinical development. At least seven products containing a form of IL-2 are in clinical development, and …

    Published on 10/27/2016
  • Figure: Both sides now

    T cell gas, tumor brake Targets & Mechanisms Both sides now Studies from two independent groups suggest targeting PGC-1α pathway functions could help treat cancer, either by enhancing the effects of T cell …

    Published on 10/27/2016
  • Figure: Both sides now

    T cell gas, tumor brake Targets & Mechanisms Both sides now Studies from two independent groups suggest targeting PGC-1α pathway functions could help treat cancer, either by enhancing the effects of T cell …

    Published on 10/27/2016
  • T cell gas, tumor brake

    Three studies pump the therapeutic potential of PGC-1α

    A trio of studies converge on a common pathway, headed by the PPAR co-activator PGC-1α, to improve T cell immunotherapies and suppress cancer metastasis.

    Published on 10/27/2016
  • Seeking cysteines

    Scripps team reveals Tecfidera's targets and how to drug them

    A Scripps team has identified PKCθ as a key target of Tecfidera and exposed a way to create isoform-selective inhibitors that extends far beyond PKC enzymes.

    Published on 10/6/2016
  • Figure: Converging on NF-κB

    Seeking cysteines Targets & Mechanisms Converging on NF-κB In a Science Signaling study published last month, researchers from The Scripps Research Institute investigated how the multiple sclerosis drug Tecfidera …

    Published on 10/6/2016
  • Figure: Targeting cysteines

    Seeking cysteines Targets & Mechanisms Targeting cysteines In a Science Signaling study published last month, researchers at The Scripps Research Institute identified two cysteines in PKCθ - Cys14 and Cys17 (yellow…

    Published on 10/6/2016
  • Figure: Targeting cysteines

    Seeking cysteines Targets & Mechanisms Targeting cysteines In a Science Signaling study published last month, researchers at The Scripps Research Institute identified two cysteines in PKCθ - Cys14 and Cys17 (yellow…

    Published on 10/6/2016
  • Table: BioCentury Product Profile

    Seeking cysteines Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Isoform-selective PKCθ inhibitor Concept A compound that suppresses T cell activation by …

    Published on 10/6/2016
  • Two-timing Ebola

    A bispecific antibody capable of neutralizing all Ebolavirus species

    The first compound to neutralize all five Ebolavirus species could provide an approach for tackling any virus with an intracellular target.

    Published on 9/29/2016
  • Hitting for the cycle

    Diversity-oriented chemistry expands the malaria drug universe

    Broad Institute scientists have identified an antimalarial compound with a new scaffold, against a new target, that hits all stages of the parasite's life cycle.

    Published on 9/29/2016
  • Table: BioCentury Product Profile

    Hitting for the cycle Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A single therapy for inhibiting all three stages of the parasite's life cycle, treating …

    Published on 9/29/2016
  • Figure: An inside job

    Two-timing Ebola Targets & Mechanisms An inside job This month in Science, a team led by researchers from the Albert Einstein College of Medicine described a "Trojan horse" bispecific antibody strategy with …

    Published on 9/29/2016
  • Table: BioCentury Product Profile

    Two-timing Ebola Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Bispecific antibody targeting all known species of Ebolavirus Concept Combines two mAbs …

    Published on 9/29/2016
  • Bon voyage!

    A Baylor team discovers how to culture norovirus, solving a 40-year-old problem

    Four decades after discovery of the norovirus, researchers have found a way to culture it in vitro that could boost chances of a vaccine.

    Published on 9/15/2016
  • Figure: Differential effect

    KOR-recting MS Targets & Mechanisms Differential effect Regrowing myelin sheaths that are lost from axons in patients with multiple sclerosis involves the proliferation of oligodendrocyte precursor cells (OPCs) in …

    Published on 9/15/2016
  • Table: BioCentury Product Profile

    KOR-recting MS Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A compound that activates kappa opioid receptor (KOR)-mediated differentiation of …

    Published on 9/15/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993